These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33064276)

  • 21. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
    Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):137-45. PubMed ID: 16515668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.
    Clouser CL; Bonnac L; Mansky LM; Patterson SE
    Antivir Chem Chemother; 2014 Dec; 23(6):223-30. PubMed ID: 23994876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
    Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.
    Grimison P; Galettis P; Manners S; Jelinek M; Metharom E; de Souza PL; Liauw W; Links MJ
    J Clin Oncol; 2007 Dec; 25(36):5704-9. PubMed ID: 18089865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic factors influencing pyrimidine-antagonist chemotherapy.
    Maring JG; Groen HJ; Wachters FM; Uges DR; de Vries EG
    Pharmacogenomics J; 2005; 5(4):226-43. PubMed ID: 16041392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
    Joerger M; Huitema AD; Koeberle D; Rosing H; Beijnen JH; Hitz F; Cerny T; Schellens JH; Gillessen S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):113-24. PubMed ID: 24166106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N; Kikuchi J; Yamauchi T; Koyama D; Wada T; Uesawa M; Akutsu M; Mori S; Nakamura Y; Ueda T; Kano Y; Furukawa Y
    PLoS One; 2014; 9(3):e90675. PubMed ID: 24626203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
    Yamamoto N; Nokihara H; Yamada Y; Uenaka K; Sekiguchi R; Makiuchi T; Slapak CA; Benhadji KA; Tamura T
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1645-55. PubMed ID: 23616084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
    Veltkamp SA; Beijnen JH; Schellens JH
    Oncologist; 2008 Mar; 13(3):261-76. PubMed ID: 18378536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
    Heinemann V; Schulz L; Issels RD; Plunkett W
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):11-8. PubMed ID: 7481839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of six pyrimidine analogs on the growth of Tetrahymena thermophila and their implications in pyrimidine metabolism.
    Harpel Z; Chang WJ; Circelli J; Chen R; Chang I; Rivera J; Wu S; Wei R
    PLoS One; 2023; 18(9):e0284309. PubMed ID: 37708236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular pharmacology of gemcitabine.
    Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
    Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does Intracellular Metabolism Render Gemcitabine Uptake Undetectable in Mass Spectrometry?
    Müller JP; Gründemann D
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
    Adema AD; Smid K; Losekoot N; Honeywell RJ; Verheul HM; Myhren F; Sandvold ML; Peters GJ
    Invest New Drugs; 2012 Oct; 30(5):1908-16. PubMed ID: 22002019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
    Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.